Pfizer’s Phase III bladder cancer therapy trial meets primary endpoint
The trial showed a 'clinically meaningful' and 'statistically significant' improvement when treated with therapy plus BCG, ...
‘Increased survival rates’ for bladder cancer patients given immunotherapy drug
Increased survival rates’ for bladder cancer patients given immunotherapy drug - Experts said Durvalumab could be a ‘game ...
Pharmabiz7h
Pfizer’s sasanlimab in combo with BCG improves EFS in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer
Pfizer’s sasanlimab in combo with BCG improves EFS in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer: New York Monday, January 13, 2025, 13:00 Hrs [IST] ...
Pfizer: My Top Play In 2025 Using Dogs Of The Dow Strategy
Pfizer is expected to rebound in 2025 with growth stabilized and dividend growth to continue. Learn why PFE stock is a Buy.
Bladder cancer patients more likely to survive with new drug
Patients in the study with advanced bladder cancer had less risk of cancer progressing or returning when treated with ...